Tryton Announces TCT Activities

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to
definitively treat bifurcation lesions, today announced that the company
will sponsor a symposium on Thursday, Sept. 23, 2010 during the
Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in
Washington, D.C.

Interim six-month results from more than 250 patients from the E-Tryton
150 and Benelux registries will be presented by David P. Foley, M.D., of
Beaumont Hospital & Royal College of Surgeons in Ireland. The symposium
will also feature additional presentations by David O. Williams, M.D. of
Brigham and Women’s Hospital in Boston, Mass.; Antonio L. Bartorelli,
M.D. of the University of Milan; Robert-Jan van Geuns, M.D., of Erasmus
University Heart Center University Hospital in Rotterdam, the
Netherlands; and Aaron V. Kaplan, M.D., of Dartmouth-Hitchcock Medical
Center in Lebanon, N.H.

“Current approaches to PCI of bifurcation lesions are diverse, and
two-stent approaches in particular can increase complexity and risk of
acute complications and restenosis down the line,” said Prof. Foley.
“The Tryton Side Branch Stent offers a simple and straightforward
approach to first securing the side branch, allowing stenting of the
main vessel using a conventional drug eluting stent. The Tryton solution
has become an important part of my clinical practice, and I look forward
to presenting additional data on the system at TCT.”

The one-hour event begins at 2:00 p.m. and will take place in the
Exhibit Hall Presentation Theater in the Washington Convention Center.

“We’re pleased that the Tryton Side Branch Stent has helped physicians
across Europe treat thousands of the most challenging interventional
cases in cardiovascular disease,” said J. Greg Davis, president and CEO
of Tryton Medical. “We look forward to demonstrating the Tryton stent
system at TCT next week.”

In addition, Prof. Foley will discuss the Tryton system in his TCT
presentation titled “The Tryton Stent: Better Than a Balloon, Equivalent
to DES in the Side Branch?” which will take place on Tuesday, Sept. 21
at 11:42 a.m. in room 152AB.

Tryton will also exhibit at the conference at booth 1357.

The Tryton Side Branch Stent System is designed to offer a dedicated
strategy for treating atherosclerotic lesions in the side branch at the
site of a bifurcation. Tryton’s highly deliverable cobalt chromium stent
is deployed in the side branch artery using a standard single-wire
balloon-expandable stent delivery system. A conventional drugeluting
stent is then placed in the main vessel.

Excellent Six-Month Clinical Results

The Tryton Side Branch Stent System demonstrated excellent six-month
clinical and angiographic results in a first-in-man study of the system
and excellent six-month clinical results from almost 200 patients in
four different registries with a rate of target lesion revascularization
of less than four percent.

The stent system has received CE Mark approval in Europe and is
commercially available in 21 countries throughout Europe and the Middle
East. It is not approved in the United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of
novel stent systems for the treatment of bifurcation lesions. The
company was founded in 2003 by Aaron V. Kaplan, M.D. (Professor of
Medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center)
and Dan Cole to develop stents for the definitive treatment of
bifurcation lesions. The Tryton Side Branch Stent System, approved for
sale in Europe, is designed to offer a dedicated strategy for treating
these challenging cases. Privately held, Tryton is backed by Arnerich
Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest
Ventures. For more information please visit trytonmedical.com.